[Poster] Puesta en Marcha de un Sistema de Cálculo Secundario de Dosis para un Acelerador Lineal con Resonancia Magnética*

*Implementation of a Secondary Dose Calculation System for a Magnetic Resonance Linear Accelerator

Rojas-López JA1,2, Cabrera-Santiago A3, Corral-Beltán JR4, García-Andino AA5
 1Hospital Angeles Puebla, Mexico
2Universidad Nacional de Córdoba, Argentina
3Hospital Almater, Mexico
4Hospital Christus Muguerza, Mexico
5PTW Latin America, Brazil

 

ABSTRACT
Purpose: To report the implementation of the secondary dose calculation software ThinkQA (TQA) v.2.0.0.60 (DOSIsoft) for a magnetic resonance-guided linear accelerator (MR-linac), following the tests of Medical Physics Practice Guideline 5.a, including dose in inhomogeneities and dose profiles.

 
Methods and Materials: 
Relative Dosimetry In Monaco v.5.51.11, fields of 2×2, 5×5, 10×10, 15×15, 20×20, and 2×20 cm² were modeled at gantry 0°, at depths of 5 and 10 cm, in an isocentric configuration to obtain dose profiles and field factors. 

Dose in Inhomogeneities In Monaco, the dose was calculated with a 10×10 cm² field and 200 MU in a water-air-water phantom.

MLC Transmission The dose was measured at 5 cm depth using a 10×10 cm² field and 200 MU, with the Exradin® chamber oriented antiparallel to the magnetic field.

Patient-Specific Quality Assurance Five intensity-modulated radiation therapy (IMRT) plans (anal, abdominal, head & neck, prostate, and lung) were measured following AAPM TG-244 guidelines. The measurements were evaluated using the 3.0%/2.0 mm gamma criterion with the ArcCheck®-MR device (SunNuclear, Melbourne, FL, USA).

Results: Relative Dosimetry – Variations of 3.8% were reported for field factors up to 2×2 cm², comparing measured data and Monaco with TQA. MLC Transmission values were 0.25%, 0.60%, and 0.50% for experimental measurements, Monaco, and TQA, respectively. Patient-Specific Quality Assurance and Planning system commissioning were also evaluated.

Conclusion: The TQA software was implemented as a secondary dose calculation system for MR-linac and was clinically validated for adaptive treatment workflow using a 3%/2 mm gamma criterion, with 95% as a tolerance limit and 90% as an action limit.